News and Events

  • Recent Releases

    03/30/2015 - 4:00pm

    Panel predicts whether rare leukemia will respond to treatment

    Patients with chronic myelomonocytic leukemia have limited treatment options, and those that exist are effective only in fewer than half of patients. Now, a new study identifies a panel of genetic markers that predicted which tumor samples would likely respond to treatment.

    03/30/2015 - 11:00am

    Researchers develop new potential drug for rare leukemia

    Researchers have developed a new drug candidate that shows potential in laboratory studies against a rare type of acute leukemia. And additional studies suggest the same compound could play a role in prostate cancer treatment as well.

    03/26/2015 - 11:45am

    U-M research on lifetime risk of ovarian cancer may help women make informed decisions

    The average lifetime risk of ovarian cancer is approximately 1.37 percent in non-Hispanic white women in the United States, but there are women at substantially higher and lower risk, according to the researchers, led by Celeste Leigh Pearce, associate professor of epidemiology.
    03/20/2015 - 10:45am

    Hovnanian Foundation gives U-M $1.65M for adrenal cancer research

    The University of Michigan Comprehensive Cancer Center received a $1.65 million gift from the Hirair and Anna Hovnanian Foundation to fund adrenal cancer research.

    03/17/2015 - 8:15pm

    Study suggests precision medicine for adrenal cancer

    In a randomized phase 3 trial, adrenal cancer patients receiving the investigational drug linsitinib fared no better than patients receiving a placebo. But the researchers noticed a small subset of patients who had significant response and remained on the drug for an extended time.

    All Releases